Effect of periodontal treatment on peak serum levels of inflammatory markers.
OBJECTIVE
Some subjects with untreated periodontitis exhibit elevated levels of distinct inflammatory markers in serum. The aim of the study was to assess whether nonsurgical periodontal therapy changes the levels of these markers and lowers these peaks.


METHODS
Forty periodontally diseased subjects received nonsurgical periodontal therapy (full-mouth scaling and root planing within 48 h) with either adjunctive systemic amoxicillin and metronidazole (n = 19) or placebo (n = 21). Serum samples, obtained at baseline (BL) and 3 months after treatment (M3), were evaluated for 15 cytokines and 9 acute-phase proteins using the Bio-Plex bead array multianalyte detection system. For each analyte, peak values were defined as greater than the mean + 2 standard deviations (SD) of measurements found in 40 periodontally healthy persons. Proportions were compared using Fisher's exact test.


RESULTS
At M3, a significantly better primary clinical outcome (persisting pockets of >4 mm with bleeding on probing) was obtained in patients treated with scaling and root planing plus antibiotics compared to those receiving placebo (3.3 ± 5.1 vs. 6.8 ± 7.8 pockets per patient, p < 0.05). The levels of cytokines and acute-phase proteins of periodontitis patients were usually below the mean + 2 SD threshold of healthy persons. However, values above threshold were found in some individuals. Eleven patients showed a peak value of one analyte, and seven patients showed two peaks. In the remaining 12 patients, between three and ten analytes showed peak values. Therapy greatly reduced the number of subjects with four or more peaks (BL, 11 subjects; M3, 1 subject, p = 0.003). With regards to the reduction of peaks, no specific benefit of adjunctive antibiotics could be seen.


CONCLUSIONS
Subjects with untreated periodontitis may show high peaks for several inflammatory markers in serum simultaneously. Nonsurgical periodontal treatment with or without antibiotics reduced most of these peak levels.
Division of Oral Physiopathology and Periodontics, School of Dental Medicine, University of Geneva, Rue Barthélemy-Menn 19, 1205, Geneva, Switzerland.
Adnan Ali
AA
Almaghlouth
Norbert
N
Cionca
José Antonio
JA
Cancela
Fabien
F
Décaillet
Delphine S
DS
Courvoisier
Catherine
C
Giannopoulou
Andrea
A
Mombelli
D000209:Acute-Phase Proteins / Q000378:metabolism*; D000658:Amoxicillin / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood*; D012534:Dental Scaling; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D010518:Periodontitis / Q000097:blood / Q000628:therapy*; D016745:Root Planing; D016896:Treatment Outcome
D000209:Acute-Phase Proteins; D000890:Anti-Infective Agents; D015415:Biomarkers; D016207:Cytokines; D008795:Metronidazole; D000658:Amoxicillin